| Ms Melissa M Anderson, FNP-C | |
|
100 N Walnut St, Seymour, IN 47274-2192 | |
| (812) 523-5185 | |
| (812) 523-3826 |
| Full Name | Ms Melissa M Anderson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 100 N Walnut St, Seymour, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396115812 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 71005821A (Indiana) | Primary |
| Entity Name | Jackson County Schneck Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629143037 PECOS PAC ID: 8224004585 Enrollment ID: O20041029000584 |
News Archive
Sinai Hospital of Baltimore takes an innovative approach to help people with diabetes mange their disease by opening the Diabetes Resource Center at Sinai. Participants who attend the center learn how to set and achieve successful medical and lifestyle goals with practical advice and emotional support.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
The nervous system is built to last a lifetime, but diverse diseases or environmental insults can overpower the capacity of neurons to maintain function or to repair after trauma. A team led by Dr. Hernán López-Schier, head of the Research Unit Sensory Biology and Organogenesis at Helmholtz Zentrum München, now succeeded in promoting the repair of an injured neural circuit in zebrafish.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Melissa M Anderson, FNP-C 100 N Walnut St, Seymour, IN 47274-2192 Ph: (812) 523-5185 | Ms Melissa M Anderson, FNP-C 100 N Walnut St, Seymour, IN 47274-2192 Ph: (812) 523-5185 |
News Archive
Sinai Hospital of Baltimore takes an innovative approach to help people with diabetes mange their disease by opening the Diabetes Resource Center at Sinai. Participants who attend the center learn how to set and achieve successful medical and lifestyle goals with practical advice and emotional support.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
The nervous system is built to last a lifetime, but diverse diseases or environmental insults can overpower the capacity of neurons to maintain function or to repair after trauma. A team led by Dr. Hernán López-Schier, head of the Research Unit Sensory Biology and Organogenesis at Helmholtz Zentrum München, now succeeded in promoting the repair of an injured neural circuit in zebrafish.
› Verified 6 days ago
Robin Elaine Cartwright, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 410 S Chestnut St, Seymour, IN 47274 Phone: 812-523-5185 | |
Ms. Rachel Elaine Hoevener, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 225 S Pine St, Jmb, 2nd Floor, Seymour, IN 47274 Phone: 812-523-7466 Fax: 812-523-7471 | |
Mrs. Cathy Robbins Hildebrand, RN, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 411 W Tipton St, Seymour, IN 47274 Phone: 812-522-0524 | |
Sarah Elizabeth Ramey, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 357 Tanger Blvd Ste 201b, Seymour, IN 47274 Phone: 812-523-3700 | |
Virginia Stewart-kinney, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 411 W Tipton St, Seymour, IN 47274 Phone: 812-522-2349 | |
Dr. Stephanie Amber Burgess, DNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1171 W Tipton St, Suite D, Seymour, IN 47274 Phone: 812-524-8780 | |
Yvonne Carmela Lucas, MSN, RN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 113 N Chestnut St Ste 100, Seymour, IN 47274 Phone: 812-524-8388 |